A. Cranston
A. Cranston
I received my BSc in Pharmacology from the University of Aberdeen in 2011 and my PhD at the biotechnology company TauRx Therapeutics, a spin-off company at the University of Aberdeen. My PhD investigated the effects of novel tau aggregation inhibitors in tau transgenic mouse models of Alzheimer’s disease, targeting cholinergic and glutamatergic impairment. In 2019, I joined the Kalia labs to study molecular mediators of α-synuclein and to investigate potential repurposing of currently approved therapies for Parkinson’s disease. My goals are to research and develop potential disease-modifying treatments for Parkinson’s disease with a specific interest on industry collaboration and clinical translation.